Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 2
1969 3
1975 1
1978 1
1980 1
1988 1
2002 2
2004 1
2005 1
2007 1
2008 1
2009 2
2010 3
2011 3
2012 1
2013 4
2014 3
2015 4
2016 3
2017 9
2018 10
2019 10
2020 18
2021 15
2022 13
2023 8
2024 12
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J. Prat A, et al. Among authors: hernando c. Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838010 Clinical Trial.
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. Hamilton E, et al. Among authors: hernando c. Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8. Ann Oncol. 2024. PMID: 38729567 Free article. Clinical Trial.
Editorial: Light-mediated regulation of plant physiology.
Romanowski A, Monte E, Hernando CE, Toledo-Ortiz G, Christie JM, Moreno-Romero J, Halliday KJ. Romanowski A, et al. Among authors: hernando ce. Front Plant Sci. 2025 Jan 3;15:1531410. doi: 10.3389/fpls.2024.1531410. eCollection 2024. Front Plant Sci. 2025. PMID: 39830939 Free PMC article. No abstract available.
Monocytes warning for malaria.
Riahi N, Tré-Hardy M, Hernando C, Blairon L, Cupaiolo R, Beukinga I. Riahi N, et al. Among authors: hernando c. Br J Haematol. 2024 Feb;204(2):379-380. doi: 10.1111/bjh.19259. Epub 2023 Dec 18. Br J Haematol. 2024. PMID: 38111310 No abstract available.
Gestational breast cancer: distinctive molecular and clinico-epidemiological features.
de la Haba-Rodríguez JR, Mínguez P, Rojo F, Martín M, Alba E, Servitja S, Prat A, Pérez-Fidalgo JA, Gavilá J, Morales C, Rodriguez-Lescure A, Herrero C, Peña-Enriquez R, Herranz J, Hernando C, Hernández-Blanquisett A, Guil-Luna S, Martinez MT, Blanch S, Caballero R, Martín N, Pollán M, Guerrero-Zotano A, Bermejo B. de la Haba-Rodríguez JR, et al. Among authors: hernando c. J Mammary Gland Biol Neoplasia. 2024 Nov 8;29(1):18. doi: 10.1007/s10911-024-09571-3. J Mammary Gland Biol Neoplasia. 2024. PMID: 39514034 Free PMC article.
Immunological Landscape of HER-2 Positive Breast Cancer.
Moragon S, Hernando C, Martinez-Martinez MT, Tapia M, Ortega-Morillo B, Lluch A, Bermejo B, Cejalvo JM. Moragon S, et al. Among authors: hernando c. Cancers (Basel). 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167. Cancers (Basel). 2022. PMID: 35804943 Free PMC article. Review.
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.
Torres-Ruiz S, Garrido-Cano I, Lameirinhas A, Burgués O, Hernando C, Martínez MT, Rojo F, Bermejo B, Tapia M, Carbonell-Asins JA, Peña CJ, Lluch A, Cejalvo JM, Tormo E, Eroles P. Torres-Ruiz S, et al. Among authors: hernando c. Cell Death Discov. 2024 Aug 22;10(1):372. doi: 10.1038/s41420-024-02128-7. Cell Death Discov. 2024. PMID: 39174500 Free PMC article.
128 results